Show simple item record

dc.contributor.authorRakhra, Kavya
dc.contributor.authorTokatlian, Talar
dc.contributor.authorIrvine, Darrell J
dc.contributor.authorHanson, Melissa Catherine
dc.date.accessioned2017-04-13T17:45:35Z
dc.date.available2017-04-13T17:45:35Z
dc.date.issued2015-10
dc.date.submitted2015-07
dc.identifier.issn0009-2665
dc.identifier.issn1520-6890
dc.identifier.urihttp://hdl.handle.net/1721.1/108119
dc.description.abstractThe immune system plays a critical role in our health. No other component of human physiology plays a decisive role in as diverse an array of maladies, from deadly diseases with which we are all familiar to equally terrible esoteric conditions: HIV, malaria, pneumococcal and influenza infections; cancer; atherosclerosis; autoimmune diseases such as lupus, diabetes, and multiple sclerosis. The importance of understanding the function of the immune system and learning how to modulate immunity to protect against or treat disease thus cannot be overstated. Fortunately, we are entering an exciting era where the science of immunology is defining pathways for the rational manipulation of the immune system at the cellular and molecular level, and this understanding is leading to dramatic advances in the clinic that are transforming the future of medicine.1,2 These initial advances are being made primarily through biologic drugs– recombinant proteins (especially antibodies) or patient-derived cell therapies– but exciting data from preclinical studies suggest that a marriage of approaches based in biotechnology with the materials science and chemistry of nanomaterials, especially nanoparticles, could enable more effective and safer immune engineering strategies. This review will examine these nanoparticle-based strategies to immune modulation in detail, and discuss the promise and outstanding challenges facing the field of immune engineering from a chemical biology/materials engineering perspectiveen_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grants AI111860, CA174795, CA172164, AI091693, and AI095109)en_US
dc.description.sponsorshipUnited States. Department of Defense (W911NF-13-D-0001 and Awards W911NF-07-D-0004)en_US
dc.language.isoen_US
dc.publisherAmerican Chemical Society (ACS)en_US
dc.relation.isversionofhttp://dx.doi.org/10.1021/acs.chemrev.5b00109en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourcePMCen_US
dc.titleSynthetic Nanoparticles for Vaccines and Immunotherapyen_US
dc.typeArticleen_US
dc.identifier.citationIrvine, Darrell J., Melissa C. Hanson, Kavya Rakhra, and Talar Tokatlian. “Synthetic Nanoparticles for Vaccines and Immunotherapy.” Chemical Reviews 115, no. 19 (October 14, 2015): 11109–11146. © 2015 American Chemical Societyen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Materials Science and Engineeringen_US
dc.contributor.departmentRagon Institute of MGH, MIT and Harvarden_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorRakhra, Kavya
dc.contributor.mitauthorTokatlian, Talar
dc.contributor.mitauthorIrvine, Darrell J
dc.contributor.mitauthorHanson, Melissa Catherine
dc.relation.journalChemical Reviewsen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsIrvine, Darrell J.; Hanson, Melissa C.; Rakhra, Kavya; Tokatlian, Talaren_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0003-2371-0470
dc.identifier.orcidhttps://orcid.org/0000-0001-8452-6752
mit.licensePUBLISHER_POLICYen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record